StockData
SLSNasdaqPharmaceutical PreparationsFiscal year ends December 31

SELLAS Life Sciences Group, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$10.49+0.51 (+5.11%)

Close on Oct 19, 2026

Market cap
$1.98B
P/E (TTM)
–
Dividend yield
–

SELLAS Life Sciences Group, Inc. revenue by segment

AnnualQuarterlyTTM

No segment breakdown reported

SELLAS Life Sciences does not break out revenue by segment, region or product in the tagged data of its filings for this period type.